Thus, IL-36β may play an important role for angiogenesis in lesional skin of AD and suppressing IL-36β signaling or expression by spesolimab or dupilumab may be associated with their effectiveness in reducing AD symptoms. This evidence concerns the gene IL36B and Alzheimer disease.